ARYx Therapeutics, which re-engineers commercially successful drugs to eliminate safety issues, priced its 5 million share offering on Wednesday at $10. The company had revised its proposed IPO range downward to $10 from $14 to $16 earlier Wednesday morning. Morgan Stanley was the lead manager on the deal, and the stock is expected to start trading on the NASDAQ under the symbol "ARYX" on Wednesday.
